Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma.

AbuHammad S, Cullinane C, Martin C, Bacolas Z, Ward T, Chen H, Slater A, Ardley K, Kirby L, Chan KT, Brajanovski N, Smith LK, Rao AD, Lelliott EJ, Kleinschmidt M, Vergara IA, Papenfuss AT, Lau P, Ghosh P, Haupt S, Haupt Y, Sanij E, Poortinga G, Pearson RB, Falk H, Curtis DJ, Stupple P, Devlin M, Street I, Davies MA, McArthur GA, Sheppard KE.

Proc Natl Acad Sci U S A. 2019 Sep 3;116(36):17990-18000. doi: 10.1073/pnas.1901323116. Epub 2019 Aug 22.

2.

First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study.

Khot A, Brajanovski N, Cameron DP, Hein N, Maclachlan KH, Sanij E, Lim J, Soong J, Link E, Blombery P, Thompson ER, Fellowes A, Sheppard KE, McArthur GA, Pearson RB, Hannan RD, Poortinga G, Harrison SJ.

Cancer Discov. 2019 Aug;9(8):1036-1049. doi: 10.1158/2159-8290.CD-18-1455. Epub 2019 May 15.

PMID:
31092402
3.

A novel immunogenic mouse model of melanoma for the preclinical assessment of combination targeted and immune-based therapy.

Lelliott EJ, Cullinane C, Martin CA, Walker R, Ramsbottom KM, Souza-Fonseca-Guimaraes F, Abuhammad S, Michie J, Kirby L, Young RJ, Slater A, Lau P, Meeth K, Oliaro J, Haynes N, McArthur GA, Sheppard KE.

Sci Rep. 2019 Feb 4;9(1):1225. doi: 10.1038/s41598-018-37883-y.

4.

Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance.

Martin CA, Cullinane C, Kirby L, Abuhammad S, Lelliott EJ, Waldeck K, Young RJ, Brajanovski N, Cameron DP, Walker R, Sanij E, Poortinga G, Hannan RD, Pearson RB, Hicks RJ, McArthur GA, Sheppard KE.

Int J Cancer. 2018 May 15;142(10):2139-2152. doi: 10.1002/ijc.31220. Epub 2018 Jan 3.

5.

Cell cycle and growth stimuli regulate different steps of RNA polymerase I transcription.

Hung SS, Lesmana A, Peck A, Lee R, Tchoubrieva E, Hannan KM, Lin J, Sheppard KE, Jastrzebski K, Quinn LM, Rothblum LI, Pearson RB, Hannan RD, Sanij E.

Gene. 2017 May 15;612:36-48. doi: 10.1016/j.gene.2016.12.015. Epub 2016 Dec 15.

PMID:
27989772
6.

Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signaling.

Quin J, Chan KT, Devlin JR, Cameron DP, Diesch J, Cullinane C, Ahern J, Khot A, Hein N, George AJ, Hannan KM, Poortinga G, Sheppard KE, Khanna KK, Johnstone RW, Drygin D, McArthur GA, Pearson RB, Sanij E, Hannan RD.

Oncotarget. 2016 Aug 2;7(31):49800-49818. doi: 10.18632/oncotarget.10452.

7.

Desmoglein 2 promotes vasculogenic mimicry in melanoma and is associated with poor clinical outcome.

Tan LY, Mintoff C, Johan MZ, Ebert BW, Fedele C, Zhang YF, Szeto P, Sheppard KE, McArthur GA, Foster-Smith E, Ruszkiewicz A, Brown MP, Bonder CS, Shackleton M, Ebert LM.

Oncotarget. 2016 Jul 19;7(29):46492-46508. doi: 10.18632/oncotarget.10216.

8.

The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma.

Ramsdale R, Jorissen RN, Li FZ, Al-Obaidi S, Ward T, Sheppard KE, Bukczynska PE, Young RJ, Boyle SE, Shackleton M, Bollag G, Long GV, Tulchinsky E, Rizos H, Pearson RB, McArthur GA, Dhillon AS, Ferrao PT.

Sci Signal. 2015 Aug 18;8(390):ra82. doi: 10.1126/scisignal.aab1111.

PMID:
26286024
9.

Enhanced GAB2 Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition.

Davis SJ, Sheppard KE, Anglesio MS, George J, Traficante N, Fereday S, Intermaggio MP, Menon U, Gentry-Maharaj A, Lubinski J, Gronwald J, Pearce CL, Pike MC, Wu A, Kommoss S, Pfisterer J, du Bois A, Hilpert F, Ramus SJ, Bowtell DD, Huntsman DG, Pearson RB, Simpson KJ, Campbell IG, Gorringe KL.

Mol Cancer Ther. 2015 Jun;14(6):1495-503. doi: 10.1158/1535-7163.MCT-15-0039. Epub 2015 Apr 7. Erratum in: Mol Cancer Ther. 2017 Mar;16(3):551.

10.

Unexpected role of CDK4 in a G2/M checkpoint.

Sheppard KE, Pearson RB, Hannan RD.

Cell Cycle. 2015;14(9):1351-2. doi: 10.1080/15384101.2015.1022060. No abstract available.

11.

Whole exome sequencing identifies a recurrent RQCD1 P131L mutation in cutaneous melanoma.

Wong SQ, Behren A, Mar VJ, Woods K, Li J, Martin C, Sheppard KE, Wolfe R, Kelly J, Cebon J, Dobrovic A, McArthur GA.

Oncotarget. 2015 Jan 20;6(2):1115-27.

12.

Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.

Young RJ, Waldeck K, Martin C, Foo JH, Cameron DP, Kirby L, Do H, Mitchell C, Cullinane C, Liu W, Fox SB, Dutton-Regester K, Hayward NK, Jene N, Dobrovic A, Pearson RB, Christensen JG, Randolph S, McArthur GA, Sheppard KE.

Pigment Cell Melanoma Res. 2014 Jul;27(4):590-600. doi: 10.1111/pcmr.12228. Epub 2014 Mar 6.

PMID:
24495407
13.

Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis.

Parmenter TJ, Kleinschmidt M, Kinross KM, Bond ST, Li J, Kaadige MR, Rao A, Sheppard KE, Hugo W, Pupo GM, Pearson RB, McGee SL, Long GV, Scolyer RA, Rizos H, Lo RS, Cullinane C, Ayer DE, Ribas A, Johnstone RW, Hicks RJ, McArthur GA.

Cancer Discov. 2014 Apr;4(4):423-33. doi: 10.1158/2159-8290.CD-13-0440. Epub 2014 Jan 27.

14.

Targeted-capture massively-parallel sequencing enables robust detection of clinically informative mutations from formalin-fixed tumours.

Wong SQ, Li J, Salemi R, Sheppard KE, Do H, Tothill RW, McArthur GA, Dobrovic A.

Sci Rep. 2013 Dec 13;3:3494. doi: 10.1038/srep03494.

15.

The cell-cycle regulator CDK4: an emerging therapeutic target in melanoma.

Sheppard KE, McArthur GA.

Clin Cancer Res. 2013 Oct 1;19(19):5320-8. doi: 10.1158/1078-0432.CCR-13-0259. Review.

16.

Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors.

Sheppard KE, Cullinane C, Hannan KM, Wall M, Chan J, Barber F, Foo J, Cameron D, Neilsen A, Ng P, Ellul J, Kleinschmidt M, Kinross KM, Bowtell DD, Christensen JG, Hicks RJ, Johnstone RW, McArthur GA, Hannan RD, Phillips WA, Pearson RB.

Eur J Cancer. 2013 Dec;49(18):3936-44. doi: 10.1016/j.ejca.2013.08.007. Epub 2013 Sep 3.

PMID:
24011934
17.

AKT-independent PI3-K signaling in cancer - emerging role for SGK3.

Bruhn MA, Pearson RB, Hannan RD, Sheppard KE.

Cancer Manag Res. 2013 Aug 26;5:281-92. doi: 10.2147/CMAR.S35178. eCollection 2013. Review.

18.

Functional analysis of genes in regions commonly amplified in high-grade serous and endometrioid ovarian cancer.

Davis SJ, Sheppard KE, Pearson RB, Campbell IG, Gorringe KL, Simpson KJ.

Clin Cancer Res. 2013 Mar 15;19(6):1411-21. doi: 10.1158/1078-0432.CCR-12-3433. Epub 2013 Jan 29.

19.

LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin.

Cowin PA, George J, Fereday S, Loehrer E, Van Loo P, Cullinane C, Etemadmoghadam D, Ftouni S, Galletta L, Anglesio MS, Hendley J, Bowes L, Sheppard KE, Christie EL, Pearson RB, Harnett PR, Heinzelmann-Schwarz V, Friedlander M, McNally O, Quinn M, Campbell P, deFazio A, Bowtell DD; Australian Ovarian Cancer Study.

Cancer Res. 2012 Aug 15;72(16):4060-73.

20.

An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice.

Kinross KM, Montgomery KG, Kleinschmidt M, Waring P, Ivetac I, Tikoo A, Saad M, Hare L, Roh V, Mantamadiotis T, Sheppard KE, Ryland GL, Campbell IG, Gorringe KL, Christensen JG, Cullinane C, Hicks RJ, Pearson RB, Johnstone RW, McArthur GA, Phillips WA.

J Clin Invest. 2012 Feb;122(2):553-7. doi: 10.1172/JCI59309. Epub 2012 Jan 3.

21.

AKT promotes rRNA synthesis and cooperates with c-MYC to stimulate ribosome biogenesis in cancer.

Chan JC, Hannan KM, Riddell K, Ng PY, Peck A, Lee RS, Hung S, Astle MV, Bywater M, Wall M, Poortinga G, Jastrzebski K, Sheppard KE, Hemmings BA, Hall MN, Johnstone RW, McArthur GA, Hannan RD, Pearson RB.

Sci Signal. 2011 Aug 30;4(188):ra56. doi: 10.1126/scisignal.2001754.

22.

Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers.

Helland Å, Anglesio MS, George J, Cowin PA, Johnstone CN, House CM, Sheppard KE, Etemadmoghadam D, Melnyk N, Rustgi AK, Phillips WA, Johnsen H, Holm R, Kristensen GB, Birrer MJ; Australian Ovarian Cancer Study Group, Pearson RB, Børresen-Dale AL, Huntsman DG, deFazio A, Creighton CJ, Smyth GK, Bowtell DD.

PLoS One. 2011 Apr 13;6(4):e18064. doi: 10.1371/journal.pone.0018064.

23.

Systematic review of reviews of intervention components associated with increased effectiveness in dietary and physical activity interventions.

Greaves CJ, Sheppard KE, Abraham C, Hardeman W, Roden M, Evans PH, Schwarz P; IMAGE Study Group.

BMC Public Health. 2011 Feb 18;11:119. doi: 10.1186/1471-2458-11-119. Review.

24.

Second AKT: the rise of SGK in cancer signalling.

Bruhn MA, Pearson RB, Hannan RD, Sheppard KE.

Growth Factors. 2010 Dec;28(6):394-408. doi: 10.3109/08977194.2010.518616. Epub 2010 Oct 5. Review.

PMID:
20919962
25.

Quality indicators for the prevention of type 2 diabetes in Europe--IMAGE.

Pajunen P, Landgraf R, Muylle F, Neumann A, Lindström J, Schwarz PE, Peltonen M, Acosta T, Adler M, AlKerwi A, Barengo N, Barengo R, Boavida JM, Charlesworth K, Christov V, Claussen B, Cos X, Cosson E, Deceukelier S, Dimitrijevic-Sreckovic V, Djordjevic P, Evans P, Felton AM, Fischer M, Gabriel-Sanchez R, Gilis-Januszewska A, Goldfracht M, Gomez JL, Greaves CJ, Hall M, Handke U, Hauner H, Herbst J, Hermanns N, Herrebrugh L, Huber C, Hühmer U, Huttunen J, Jotic A, Kamenov Z, Karadeniz S, Katsilambros N, Khalangot M, Kissimova-Skarbek K, Köhler D, Kopp V, Kronsbein P, Kulzer B, Kyne-Grzebalski D, Lalic K, Lalic N, Landgraf R, Lee-Barkey YH, Liatis S, Lindström J, Makrilakis K, McIntosh C, McKee M, Mesquita AC, Misina D, Muylle F, Neumann A, Paiva AC, Pajunen P, Paulweber B, Peltonen M, Perrenoud L, Pfeiffer A, Pölönen A, Puhl S, Raposo F, Reinehr T, Rissanen A, Robinson C, Roden M, Rothe U, Saaristo T, Scholl J, Schwarz PE, Sheppard KE, Spiers S, Stemper T, Stratmann B, Szendroedi J, Szybinski Z, Tankova T, Telle-Hjellset V, Terry G, Tolks D, Toti F, Tuomilehto J, Undeutsch A, Valadas C, Valensi P, Velickiene D, Vermunt P, Weiss R, Wens J, Yilmaz T.

Horm Metab Res. 2010 Apr;42 Suppl 1:S56-63. doi: 10.1055/s-0029-1240976. Epub 2010 Apr 13.

26.

Take action to prevent diabetes--the IMAGE toolkit for the prevention of type 2 diabetes in Europe.

Lindström J, Neumann A, Sheppard KE, Gilis-Januszewska A, Greaves CJ, Handke U, Pajunen P, Puhl S, Pölönen A, Rissanen A, Roden M, Stemper T, Telle-Hjellset V, Tuomilehto J, Velickiene D, Schwarz PE, Acosta T, Adler M, AlKerwi A, Barengo N, Barengo R, Boavida JM, Charlesworth K, Christov V, Claussen B, Cos X, Cosson E, Deceukelier S, Dimitrijevic-Sreckovic V, Djordjevic P, Evans P, Felton AM, Fischer M, Gabriel-Sanchez R, Gilis-Januszewska A, Goldfracht M, Gomez JL, Greaves CJ, Hall M, Handke U, Hauner H, Herbst J, Hermanns N, Herrebrugh L, Huber C, Hühmer U, Huttunen J, Jotic A, Kamenov Z, Karadeniz S, Katsilambros N, Khalangot M, Kissimova-Skarbek K, Köhler D, Kopp V, Kronsbein P, Kulzer B, Kyne-Grzebalski D, Lalic K, Lalic N, Landgraf R, Lee-Barkey YH, Liatis S, Lindström J, Makrilakis K, McIntosh C, McKee M, Mesquita AC, Misina D, Muylle F, Neumann A, Paiva AC, Pajunen P, Paulweber B, Peltonen M, Perrenoud L, Pfeiffer A, Pölönen A, Puhl S, Raposo F, Reinehr T, Rissanen A, Robinson C, Roden M, Rothe U, Saaristo T, Scholl J, Schwarz PE, Sheppard KE, Spiers S, Stemper T, Stratmann B, Szendroedi J, Szybinski Z, Tankova T, Telle-Hjellset V, Terry G, Tolks D, Toti F, Tuomilehto J, Undeutsch A, Valadas C, Valensi P, Velickiene D, Vermunt P, Weiss R, Wens J, Yilmaz T.

Horm Metab Res. 2010 Apr;42 Suppl 1:S37-55. doi: 10.1055/s-0029-1240975. Epub 2010 Apr 13.

PMID:
20391307
27.

A European evidence-based guideline for the prevention of type 2 diabetes.

Paulweber B, Valensi P, Lindström J, Lalic NM, Greaves CJ, McKee M, Kissimova-Skarbek K, Liatis S, Cosson E, Szendroedi J, Sheppard KE, Charlesworth K, Felton AM, Hall M, Rissanen A, Tuomilehto J, Schwarz PE, Roden M, Paulweber M, Stadlmayr A, Kedenko L, Katsilambros N, Makrilakis K, Kamenov Z, Evans P, Gilis-Januszewska A, Lalic K, Jotic A, Djordevic P, Dimitrijevic-Sreckovic V, Hühmer U, Kulzer B, Puhl S, Lee-Barkey YH, AlKerwi A, Abraham C, Hardeman W, Acosta T, Adler M, AlKerwi A, Barengo N, Barengo R, Boavida JM, Charlesworth K, Christov V, Claussen B, Cos X, Cosson E, Deceukelier S, Dimitrijevic-Sreckovic V, Djordjevic P, Evans P, Felton AM, Fischer M, Gabriel-Sanchez R, Gilis-Januszewska A, Goldfracht M, Gomez JL, Greaves CJ, Hall M, Handke U, Hauner H, Herbst J, Hermanns N, Herrebrugh L, Huber C, Hühmer U, Huttunen J, Jotic A, Kamenov Z, Karadeniz S, Katsilambros N, Khalangot M, Kissimova-Skarbek K, Köhler D, Kopp V, Kronsbein P, Kulzer B, Kyne-Grzebalski D, Lalic K, Lalic N, Landgraf R, Lee-Barkey YH, Liatis S, Lindström J, Makrilakis K, McIntosh C, McKee M, Mesquita AC, Misina D, Muylle F, Neumann A, Paiva AC, Pajunen P, Paulweber B, Peltonen M, Perrenoud L, Pfeiffer A, Pölönen A, Puhl S, Raposo F, Reinehr T, Rissanen A, Robinson C, Roden M, Rothe U, Saaristo T, Scholl J, Schwarz PE, Sheppard KE, Spiers S, Stemper T, Stratmann B, Szendroedi J, Szybinski Z, Tankova T, Telle-Hjellset V, Terry G, Tolks D, Toti F, Tuomilehto J, Undeutsch A, Valadas C, Valensi P, Velickiene D, Vermunt P, Weiss R, Wens J, Yilmaz T.

Horm Metab Res. 2010 Apr;42 Suppl 1:S3-36. doi: 10.1055/s-0029-1240928. Epub 2010 Apr 13.

28.
29.

Cross talk between corticosteroids and alpha-adrenergic signalling augments cardiomyocyte hypertrophy: a possible role for SGK1.

Lister K, Autelitano DJ, Jenkins A, Hannan RD, Sheppard KE.

Cardiovasc Res. 2006 Jun 1;70(3):555-65. Epub 2006 Feb 14.

PMID:
16533503
30.
31.

Corticosteroid receptors, 11 beta-hydroxysteroid dehydrogenase, and the heart.

Sheppard KE.

Vitam Horm. 2003;66:77-112. Review.

PMID:
12852253
32.

Nuclear receptors. II. Intestinal corticosteroid receptors.

Sheppard KE.

Am J Physiol Gastrointest Liver Physiol. 2002 May;282(5):G742-6. Review.

33.
34.

Novel nuclear corticosteroid binding in rat small intestinal epithelia.

Sheppard KE, Hourigan S, Li KX, Krozowski ZS.

Am J Physiol Gastrointest Liver Physiol. 2000 Sep;279(3):G536-42.

35.

Corticosteroid receptors and 11beta-hydroxysteroid dehydrogenase isoforms in rat intestinal epithelia.

Sheppard KE, Li KX, Autelitano DJ.

Am J Physiol. 1999 Sep;277(3):G541-7. doi: 10.1152/ajpgi.1999.277.3.G541.

PMID:
10484378
36.

The type I and type II 11beta-hydroxysteroid dehydrogenase enzymes.

Krozowski Z, Li KX, Koyama K, Smith RE, Obeyesekere VR, Stein-Oakley A, Sasano H, Coulter C, Cole T, Sheppard KE.

J Steroid Biochem Mol Biol. 1999 Apr-Jun;69(1-6):391-401. Review.

PMID:
10419017
37.

Steroid specificity of the putative DHB receptor: evidence that the receptor is not 11betaHSD.

Sheppard KE, Khoo K, Krozowski ZS, Li KX.

Am J Physiol. 1998 Jul;275(1):E124-31. doi: 10.1152/ajpendo.1998.275.1.E124.

PMID:
9688883
39.

Mineralocorticoid receptors, salt, and hypertension.

Funder JW, Krozowski Z, Myles K, Sato A, Sheppard KE, Young M.

Recent Prog Horm Res. 1997;52:247-60; discussion 261-2. Review.

PMID:
9238855
40.

cAMP modulates glucocorticoid-induced protein accumulation and glucocorticoid receptor in cardiomyocytes.

Sato A, Sheppard KE, Fullerton MJ, Funder JW.

Am J Physiol. 1996 Nov;271(5 Pt 1):E827-33.

PMID:
8944668
41.
43.

Glucocorticoid receptor expression is down-regulated by Lp(a) lipoprotein in vascular smooth muscle cells.

Sato A, Sheppard KE, Fullerton MJ, Sviridov DD, Funder JW.

Endocrinology. 1995 Sep;136(9):3707-13.

PMID:
7649076
44.
45.
46.

Glucocorticoid receptor function in rat pituitary intermediate lobe is inhibited by an endogenous protein.

Sheppard KE, Autelitano DJ, Roberts JR, Blum M.

J Neuroendocrinol. 1993 Apr;5(2):195-200.

PMID:
7683558
48.
49.
50.

Cortisol 17 beta acid, transcortin, and the heterogeneity of rat brain glucocorticoid receptors.

Sheppard KE, Funder JW.

J Steroid Biochem. 1986 Aug;25(2):285-8.

PMID:
3747528

Supplemental Content

Loading ...
Support Center